APA (7th ed.) Citation

L, A., LA, A., ES, B., B, B., EF, B., MB, B., . . . B, N. (2025). Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives. Clinical breast cancer, 25(6), e721. https://doi.org/10.1016/j.clbc.2025.04.011

Chicago Style (17th ed.) Citation

L, Asphaug, et al. "Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives." Clinical Breast Cancer 25, no. 6 (2025): e721. https://doi.org/10.1016/j.clbc.2025.04.011.

MLA (9th ed.) Citation

L, Asphaug, et al. "Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives." Clinical Breast Cancer, vol. 25, no. 6, 2025, p. e721, https://doi.org/10.1016/j.clbc.2025.04.011.